Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors

April 2015 | 414 pages | ID: CC323B4AD9FEN
La Merie Publishing

Abstracts

Competitor Analysis: The rapeutic Antibodies 2015: Biosimilars & Biosuperiors

This Competitive Intelligence Report about The rapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of April 2015.

Total sales of recombinant therapeutic monoclonal antibodies originating from companies located in regulated markets reached US$ 82. 2 bln (+8. 6% vs previous year) in the year 2014.

The report lists specifically for each target the branded products with their 2014 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development.

The report includes a compilation of currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets:

• VEGF
• TNF
• Her2
• CD20
• EGF-R
• B7. 1/B7. 2 (CD80/CD86)
• IL-6R
• Alpha4/beta1/7 integrin
• IgE
• RSV
• RANKL
• Complement C5
• IL-12/IL-23
• CD52

Download sample pages of Competitor Analysis: The rapeutic Antibodies 2015 - Biosimilars & Biosuperiors

Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Contents

1) 2014 Sales of Therapeutic Antibodies

  Anti-TNF Antibody Sales 2014
  Cancer Antibody Sales 2014
  Other Anti-Inflammatory Antibody Sales 2014
  Ophthalmic Antibody Sales 2014
  Cardiometabolic & Antiviral Antibody Sales 2014

2) VEGF Antibodies

Marketed VEGF & VEGF-R Antibodies in Oncology:
  Avastin Sales & Pipeline
  Zaltrap Sales & Pipeline
  Cyramza Sales & Pipeline
Avastin & Zaltrap Biosuperiors:
  Anti-VEGF & Antibody Combination Pipeline
  Bispecific Anti-VEGF Antibody Pipeline
Cyramza Biosuperiors:
  Anti-VEGF-R & Antibody Combination Pipeline
  Bispecific Anti-VEGF-R Antibody Pipeline
Avastin Biosimilar Pipeline:
Marketed VEGF Antibodies in Ophthalmology:
  Lucentis Sales & Pipeline
  Eylea Sales & Pipeline
Biosuperior Lucentis & Eylea Pipeline:
  Anti-VEGF Pipeline in Ophthalmology
  Bispecific Anti-VEGF and Antibody Combination Pipeline in Ophthalmology
Lucentis Biosimilar Pipeline

3) TNF Antibodies

Tab. 1: Approved and marketed indications of anti-TNF antibodies in regulated markets
Tab. 2: Additional indications of branded anti-TNF antibodies under development
Tab. 3: 2014 Sales of anti-TNF Antibodies
Marketed TNF Antibodies
  Humira Sales & Pipeline
  Remicade Sales & Pipeline
  Enbrel Sales & Pipeline
  Simponi Sales & Pipeline
  Cimzia Sales & Pipeline
Biosuperior / Biobetter TNF Antibodies
Biosimilar TNF Antibodies
  Humira Biosimilar Antibody Pipeline
  Remicade Biosimilar Antibody Pipeline
  Enbrel Biosimilar Antibody Pipeline
  Cimzia Biosimilar Antibody Pipeline

4) Her2 Antibodies

Marketed Her2 Antibodies
  Herceptin Sales & Pipeline
  Perjeta Sales & Pipeline
  Kadcyla Sales & Pipeline
Trastuzumab Biosuperiors
  Engineered Her2 Antibodies
  Bi- and Multispecific Her2 Antibodies
  Her2 Antibody-Drug Conjugates
  Other Her2 Antibodies
Herceptin Biosimilars

5) CD20 Antibodies

2014 Sales of CD20 Antibodies
Marketed CD20 Antibodies & Sales
  Rituxan/MabThera Pipeline & Sales
  Gazyva/ Gazyvaro Pipeline & Sales
  Arzerra Pipeline & Sales
  Zevalin Pipeline & Sales
Biosuperior CD20 Antibodies
Biosimilar CD20 Antibodies
  Rituxan/MabThera (rituximab) Biosimilars

6) EGF-R Antibodies

2014 Sales of EGF-R Antibodies
Marketed EGF-R Antibodies
  Erbitux Sales & Pipeline
  Vectibix Sales & Pipeline
  Nimotuzumab Pipeline
EGF-R Antibody Biosuperiors
  Engineered EGF-R Antibodies
  Bi- and Multispecific EGF-R Antibodies
  EGF-R Antibody-Drug Conjugates
EGF-R Antibody Biosimilars
  Cetuximab Biosimilars

7) RANKL Antibodies

Marketed RANKL Antibodies
  Prolia Sales & Pipeline
  XGEVA Sales & Pipeline
  Ranmark/Pralia Pipeline
Biosuperior RANKL Antibodies
Biosimilar RANKL Antibodies

8) Complement C5 Antibodies

Marketed C5 Antibody Sales & Pipeline
Biosuperior C5 Antibodies
Biosimilar C5 Antibodies

9) Interleukin-12/-23 Antibodies

Marketed IL-12/-23 Antibody Sales & Pipeline

10) Alpha4/Beta1/7 Antibodies

Marketed alpha4/beta1/7 Antibody Sales & Pipeline

11) IgE Antibodies

Marketed IgE Antibody Sales & Pipeline
Biosuperior IgE Antibodies
Biosimilar IgE Antibodies

12) CD80/86 (B7-1/B7-2) Antibodies

Marketed CD80/86 Antibodies Sales & Pipeline
Biosuperior CD80/86 Antibodies
Biosimilar CD80/86 Antibodies

13) Interleukin-6 Receptor (IL-6R) Antibodies

Marketed IL-6R Antibody Sales & Pipeline
Biosuperior IL-6R Antibodies
Biosimilar IL-6R Antibodies

14) Respiratory Syncytial Virus (RSV) Antibodies

Marketed RSV Antibody Sales
Biosuperior RSV Antibodies
Biosimilar RSV Antibodies

15) CD52 Antibodies

Marketed CD52 Antibody Sales
Biosuperor CD52 Antibodies
Biosimilar CD52 Antibodies

Corporate Therapeutic Antibody Biosimilar & Biosuperior Pipelines